[331] Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali J-R. Impairment of coronary reserve and Ach-induced coronary vasodilation in diabetic patients with angiopathically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993; 42: 1017-25.
[332] Strauer BE, Motz W, Vogt M, Schwarztkopff B. Impaired coronary flow reserve in NIDDM. A possible role fordiabetic cardiopathy in humans. Diabetes 1997; 46 (suppl 2): S119-24.
[333] Schernthaner G. Progress in the immunointervention of type 1 diabetes mellitus. Horm Metab Res 1995; 27: 547-54.
[334] Becker DJ, LaPorte RE, Libman I, Pietropaolo M, Dosch HM. Prevention of type 1 diabetes: is now the time ? J Clin Endocrin Metab 2000; 85: 498-506.
[335] Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325: 147-52.
[336] Eriksson KF, Lindgräde F. Prevention of type II (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991; 34: 891-8.
[337] Tuomilethto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kinkaanniemi S, Uusitupa M, for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
[338] Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC, Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-7.
[339] King H, Dowd JE. Primary prevention of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 3-8.
[340] Chiasson JL. Konzepte für primäre Prävention des nicht insulinabhängigen Diabetes mellitus (NIDDM). In: Hanefeld M, Leonhardt W, editors. Das metabolische Syndrom. Stuttgart: Gustav Fischer Verlag; 1996:89-95.
[341] Hanefeld M, Temelkowa-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997; 14: S6-11.
[342] Shaw JE, Hodge AM, deCourten M, Chatson P, Zimmett PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-4.
[343] Berghe G van den, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-67.
[344] Deutsche Diabetes Gesellschaft. Evidenzbasierte Diabetes-Leitlinie DDG–Diskussionsentwurf: Therapieziele und Behandlungsstrategien beim Diabetes mellitus. Diabetes Stoffw 1999; 8 (suppl 3): 25-36.
[345] Gries FA. Das Arzt-Patienten-Verhältnis bestimmt das Krankheitserlebnis und Management des Diabetes mellitus. In: Herpertz S, Paust R, editors. Psychosoziale Aspekete in Diagnostik und Therapie des Diabetes mellitus, Lengerich, Berlin: Pabst Science Publ; 1999: 125-36.
[346] Skinner TC, Cradock S. Empowerment: what about the evidence ? Pract Diab Int 2000; 17: 91-5.
[347] Assal JP, Mühlhauser I, Pernet A, Gfeller R, Jörgens V, Berger M. Patient education as the basis for diabetes care in clinical practice and research. Diabetologia 1985; 28: 602-13.
[348] Berger M, Jörgens V, Mühlhauser J, Zimmermann H. Die Bedeutung der Diabetikschulung in der Therapie des Typ 1 Diabetes. Dtsch Med Wochenschr 1983; 109: 424-30.
[349] The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Recommendations for the nutritional management of patients with diabetes mellitus. Eur J Clin Nutrit 2000; 54: 353-5.
[350] Grüsser M, Bott U, Eltermann P, Kronsbein P, Jörgens V. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after introduction of nationwide financing. Diabetes Care 1993; 16: 1268-75.
[351] Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, diVincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmakokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-8.
[352] Andersen JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMardi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin dependent diabetes mellitus. Arch Intern Med 1997; 157: 1249-55.
[353] Andersen JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMardi R, Multicenter Insulin Lispro Study Group. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997; 19: 62-71.
[354] Heinemann L. Hypoglycaemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications 1999; 13: 105-14.
[355] Renner R, Pfützner A, Trautmann M, Harzer O, Santer K. Landgraf R, on behalf of the German Humalog-CSII Study Group. Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial. Diabetes Care 1999; 22: 784-8.
[356] Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng S-L. Gelfand RA, for the Inhaled Insulin Phase II Study Group: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-5.
[357] Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S-L, Galfand RA, for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-7.
[358] Gale EAM, Two cheers for inhaled insulin. Lancet 2001; 357: 324-5.
[359] Nathan DM. Inhaled insulin for type 2 diabetes: solution or distraction? Ann Intern Med 2001; 134: 242-4.
[360] Hansen BF, Danielsen GM, Drejer K, Sörensen AR, Wiberg FC, Klein HH, Lundemore AG. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315: 271-9.
[361] Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, Surface PL, Chance RE. Modifications in the B10 and B26- 30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40: S54-61.
[362] Kurtzhals P, Schäffer L, Sörensen A, Kristensen C, Jonassen J, Schmid C, Trüb T. Correlations of receptorbinding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
[363] Fölsch UR, Ebert R, Creutzfeldt W. Response of serum levels of gastric inhibitory polypeptide and insulin to sucrose ingestion during long-term application of acarbose. Scand J Gastroenterol 1981; 16: 629-32.
[364] Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TMS. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190-3.
[365] Lebowitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45.
[366] Mertes G. Efficacy and safety of acarbose in the type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pract 1998; 40: 63-70.
[367] Pinol C, Guardiola E, Soler J, Cano F, Hernandez-Mijares A, Jimenez A, Leiva A de, Arroyo JA. A double blind, randomised, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic